Julio A.
- Country
- Spain
- Department
- Pneumology
Research Overview
- A Randomized Controlled Trial Comparing the Efficacy of Umeclidinium Bromide, Fluticasone Furoate, and Vilanterol Versus LABA-LAMA Combination in High-Risk COPD Patients
- Phase II Randomized Trial Evaluating Loratadine and Sirolimus in Lymphangioleiomyomatosis Patients
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Data & Insights
Has run more than one trial at 9 of 146 partner sites.
Specializations
Respiratory Medicine
The investigator specializes in treating Chronic Obstructive Pulmonary Disease (COPD), with particular focus on high-risk patients and clinical control optimization strategies. Their research explores innovative therapeutic approaches in respiratory medicine.
- COPD Management
- Clinical Control Assessment
- Treatment Optimization
Expertise includes evaluation of combination therapies for improving patient outcomes in respiratory conditions.
Rare Diseases
The investigator conducts research in Lymphangioleiomyomatosis (LAM), a rare lung disease affecting predominantly women. Their work focuses on novel therapeutic combinations to improve treatment outcomes.
- LAM Treatment Strategies
- Combination Therapy Assessment
- Drug Safety Evaluation
Specialized interest in developing innovative treatment approaches for rare respiratory conditions.
Clinical Pharmacology
The investigator evaluates therapeutic combinations in respiratory medicine, focusing on safety profiles and clinical efficacy of various drug combinations.
- Drug Interaction Studies
- Safety Profile Assessment
- Long-term Treatment Outcomes
Expertise in monitoring treatment responses and adverse event profiles in complex respiratory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.